Novartis Ag

Glaxosmithkline LLC

Stephen Carl McKeown

Steven John Charlton

Catherine Leblanc

Catherine LeBlanc

Nicola Tufilli

Anett Perlberg

Terrence Lee Smalley, Jr

Rebecca Butler

Andrew James Peat

David Francis Corbett

Kate Anna Dwornik

Dulce Maria Garrido

Wendy Yoon Mills

The present invention provides heterocyclic derivatives of formula (Ia) which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. 

IP receptor agonist heterocyclic compounds

The invention relates to salts of (7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid which are useful for treating diseases affected by the activation of the IP receptor, pharmaceutical compositions that contain the salts and processes for preparing the salts are also described.

Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists

The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples. 

Substituted pyrido[2,3-B]pyrazines as IP receptor agonists

The present invention provides substituted pyrido[2,3-b]pyrazines which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such substituted pyride[2,3-b]pyrazines are also encompassed.

Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist

The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.

Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40

Growing community of inventors

Hitchin, United Kingdom

Stephen Carl McKeown